Compare ICU & BNGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICU | BNGO |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3M | 12.5M |
| IPO Year | 2021 | 2018 |
| Metric | ICU | BNGO |
|---|---|---|
| Price | $2.21 | $1.15 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | ★ $10.00 | $5.00 |
| AVG Volume (30 Days) | ★ 220.8K | 202.8K |
| Earning Date | 11-12-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 94.50 |
| EPS | ★ N/A | N/A |
| Revenue | $1,234,000.00 | ★ $12,000,735.00 |
| Revenue This Year | $62.07 | $13.91 |
| Revenue Next Year | $46.55 | $33.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 814.07 | 26.26 |
| 52 Week Low | $0.22 | $1.00 |
| 52 Week High | $5.38 | $2.23 |
| Indicator | ICU | BNGO |
|---|---|---|
| Relative Strength Index (RSI) | 33.81 | 34.63 |
| Support Level | N/A | $1.10 |
| Resistance Level | $2.82 | $1.19 |
| Average True Range (ATR) | 0.30 | 0.07 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 1.12 | 15.63 |
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.